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1On the basis of robust scientific1,2 and clinical outcome data derived from large randomized controlled trials and reg-
istries,3–18 fractional flow reserve (FFR) has become the stan-
dard for clinical decision making about percutaneous coronary 
revascularization.19 FFR has a Class I indication with a level 
of evidence A in stable patients to identify hemodynamically 
significant coronary lesions when evidence of ischemia is 
not available.19 Recent prospective outcome data, obtained in 
medically treated patients, indicated a risk continuum for FFR 
values from 0 to 1, where the lower the FFR the higher the 
long-term event rate.18,20 However, it is still unclear whether 
a similar correlation is maintained after revascularization 
because the clinical value of FFR to evaluate the results of per-
cutaneous coronary intervention (PCI) has not been prospec-
tively investigated in the drug-eluting stent (DES) era.
Accordingly, we investigated the potential of post-PCI 
FFR measurements to predict clinical outcome in a large 
cohort of patients enrolled in the FAME trials.
Background—The predictive value of fractional flow reserve (FFR) measured immediately after percutaneous coronary 
intervention (PCI) with drug-eluting stent placement has not been prospectively investigated. We investigated the 
potential of post-PCI FFR measurements to predict clinical outcome in patients from FAME 1 and 2 trials (Fractional 
Flow Reserve or Angiography for Multivessel Evaluation).
Methods and Results—All patients of FAME 1 and FAME 2 who had post-PCI FFR measurement were included. The primary 
outcome was vessel-oriented composite end point at 2 years, defined as vessel-related cardiovascular death, vessel-related 
spontaneous myocardial infarction, and ischemia-driven target vessel revascularization. Eight hundred thirty-eight vessels 
in 639 patients were analyzed. Baseline FFR values did not differ between vessels with versus without vessel-oriented 
composite end point (0.66±0.11 versus 0.63±0.14, respectively; P=0.207). Post-PCI FFR was significantly lower in 
vessels with vessel-oriented composite end point (0.88±0.06 versus 0.90±0.06, respectively; P=0.019). Comparing the 
2-year outcome of lower and upper tertiles of post-PCI FFR significant difference was found favoring upper tertile in 
terms of overall vessel-oriented composite end point (9.2% versus 3.8%, respectively; hazard ratio, 1.46; 95% confidence 
interval, 1.02–2.08; P=0.037) and target vessel revascularization (7.0% versus 2.4%, respectively; hazard ratio, 1.59; 
95% confidence interval, 1.03–2.46; P=0.037). When adjusted to sex, hypertension, diabetes mellitus, target vessel, serial 
stenosis, and baseline percentage diameter stenosis, a strong trend was preserved in terms of target vessel revascularization 
(harzard ratio, 1.55; 95% confidence interval, 0.97–2.46; P=0.066), favoring the upper tertile. Post-PCI FFR of 0.92 was 
found to have the highest diagnostic accuracy; however, the positive likelihood ratio remained low (<1.4).
Conclusions—A higher post-PCI FFR value is associated with a better vessel-related outcome. However, its predictive 
value is too low to advocate its use as a surrogate clinical end point.  (Circ Cardiovasc Interv. 2017;10:e005233. DOI: 
10.1161/CIRCINTERVENTIONS.116.005233.)
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Methods
Patients
The design and results of the FAME 1 and FAME 2 studies have been 
reported previously.5–7,9 Both are international, multicenter, prospective, 
randomized clinical trials with comparable inclusion and exclusion cri-
teria. In brief, the FAME 1 trial enrolled patients with angiographic 
multivessel coronary artery disease amenable for PCI. Patients were 
randomized either to an FFR-guided or to an angiography-guided ap-
proach. In the FFR-guided arm, only lesions with an FFR ≤0.80 were 
treated by PCI, whereas in the angiography-guided arm, all narrow-
ings with ≥50% diameter stenosis (DS) were treated by PCI. Stenting 
was performed using first-generation DES. The primary end point 
was the composite of all-cause death, nonfatal myocardial infarction 
(MI), and any repeat revascularization (major adverse cardiac events 
[MACE]) at 1 year as adjudicated by a clinical event committee. A 
prespecified secondary end point of the study was the MACE rate at 2 
years.17 The FAME 2 trial enrolled patients with stable angina, stabi-
lized acute coronary syndrome or silent ischemia with 1, 2, or 3-vessel 
disease. Patients having at least one stenosis with an FFR ≤0.80 were 
randomized to FFR-guided PCI plus best available medical therapy or 
best available medical therapy alone. PCI was performed using second-
generation DES. The primary end point of the study was a composite of 
all-cause death, nonfatal MI, and unplanned hospitalization leading to 
urgent revascularization at 2 years. A prespecified secondary end point 
of the study was any repeat revascularization at 2 years.7 In both trials, 
patients were included only if there was at least one clearly identifiable 
focal narrowing at angiography deemed to be amenable for stenting. 
Patients with only diffuse disease were not considered for the study as 
it was supposed that no local treatment (stenting) might significantly 
improve vessel hemodynamics.
The present analysis includes all patients who had post-PCI FFR 
measurement from the FFR-guided arm of the FAME 1 trial and the 
PCI plus best available medical therapy arm of the FAME 2 trial. 
Obtaining post-PCI FFR was not mandated per protocol. Institutional 
research board has approved the present study. All patients gave in-
formed consent before enrollment to FAME 1 or FAME 2 trials.
Vessels
The present study investigated the relationship between post-PCI 
FFR values and clinical outcome at vessel level. All angiographic 
characteristics and end points are reported at vessel level. Coronary 
stenosis severity was assessed by visual estimation and reported, ac-
cording to the main trials, in the following strata of DS: <50%, 50% 
to 69%, 70% to 90%, and >90%.
End Points
Follow-up was censored 2 years after enrollment or at the time of 
death. The primary end point of the present analysis is the vessel-
oriented composite end point (VOCE) at 2 years, defined as the 
composite of vessel-related cardiovascular death, vessel-related 
spontaneous (ie, nonperiprocedural) MI, and ischemia-driven tar-
get vessel revascularization (TVR, both urgent and nonurgent). All 
events were adjudicated by an independent clinical event commit-
tee, blinded to randomization allocation. For the present analysis, all 
the original narratives were reviewed and evaluated independently by 
2 interventional cardiologists (Z.P. and G.G.T.), blinded to baseline 
clinical and procedural characteristics, as well as to post-PCI FFR 
value. Events were designated as vessel-related or not vessel-related. 
WHAT IS KNOWN
• Fractional flow reserve with a clear cutoff value of 
0.80 is the current gold standard for invasive hemo-
dynamic evaluation of coronary stenoses.
• True prognostic value of fractional flow reserve, 
measured right after percutaneous coronary inter-
vention with drug-eluting stent is unknown.
WHAT THE STUDY ADDS
• Low post–percutaneous coronary intervention frac-
tional flow reserve is associated with worse long-
term clinical outcome on vessel level.
• However, after percutaneous coronary intervention, 
there is no well-defined fractional flow reserve cutoff 
value, which could be applied for individual clinical de-
cisions or used as surrogate end point in future studies.
Table 1. Clinical Characteristics of the Patient Population
 Total FAME 1 FAME 2 P Value
Patients out of the study, n (%) 639 (67) 352 (69) 287 (64) 0.232
Age, y (mean±SD) 64±10 65±10 63±9 0.114
BMI, kg/m2 (mean±SD) 28±5 28±5 28±4 0.618
Male sex, n (%) 506 (79) 281 (80) 225 (78) 0.906
Hypertension, n (%) 435 (68) 211 (68) 224 (78) <0.001
Dyslipidemia, n (%) 472 (74) 254 (72) 218 (76) 0.554
Diabetes mellitus, n (%) 159 (25) 81 (23) 78 (27) 0.480
Smoker, n (%) 152 (24) 94 (27) 58 (20) 0.159
Family history, n (%) 271 (42) 135 (38) 136 (47) 0.071
Previous PCI, n (%) 145 (23) 90 (26) 55 (19) 0.158
Previous MI, n (%) 284 (37) 127 (36) 111 (39) 0.796
CCS
  1 171 (27) 91 (26) 80 (28)  
  2 251 (39) 116 (33) 135 (47)  
  3 143 (22) 94 (27) 49 (17)  
  4 74 (12) 51 (14) 23 (8) 0.002
Comparison of population from FAME 1 and FAME 2 trials. BMI indicates 
body mass index; CCS, Canadian Cardiovascular Society; FAME, Fractional Flow 
Reserve or Angiography for Multivessel Evaluation; MI, myocardial infarction; 
and PCI, percutaneous coronary intervention.
Figure 1. Distribution of post–percutaneous coronary interven-
tion (PCI) fractional flow reserve (FFR) values. Colors indicate the 
lower (<0.88; red), the middle (0.88–0.92; orange), and the upper 
(>0.92; green) tertiles according to post-PCI FFR groups.
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In case of disagreement, the narrative was reviewed again until a joint 
agreement was met. Death was categorized as either cardiovascular 
or noncardiovascular. Any death of unknown cause was counted as 
cardiovascular. Cardiovascular death in patients with multiple index 
stenoses was assigned to each index stenosis. Any spontaneous MI 
without clearly identifiable culprit vessel was counted as target vessel 
related. Any spontaneous MI in patients with multiple index stenoses 
without clearly identifiable culprit vessel was assigned to each index 
stenosis.
Statistical Analysis
Continuous variables are presented as mean±SD or median and inter-
quartile range from the 25th to the 75th percentile; categorical data 
are presented as numbers and percentages, as appropriate. Normal 
distribution was tested with D’Agostino K2 test. Comparisons 
between continuous variables were performed using Student t test or 
Mann–Whitney test, as appropriate. Comparisons between categori-
cal variables were evaluated using Pearson χ2 or Fisher exact test, as 
appropriate. The predictive value of clinical and angiographic param-
eters on post-PCI FFR was determined by deriving the β-coefficient 
in a generalized linear mixed-effects regression model after standard-
ization to achieve that the variance of dependent and independent 
variable was 1. Sensitivity, specificity, and optimal diagnostic cutoff 
values were defined from the calculated receiver–operator character-
istic curves, as appropriate. In lesion-level–based analysis, general 
procedural characteristics and generalized mixed-effects models were 
used with patient identification as random effect to account for the 
nonindependence of lesions within the same patient. The multilevel 
mixed-effects model used for lesion-level analyses fitted random 
intercepts to account for the correlation of characteristics of lesions 
within patients. In analysis of time-to-event outcomes, Cox regres-
sion was used with robust SE to account for the correlation between 
lesions. Proportional-hazards test based on Schoenfeld residuals was 
performed after fitting a crude and adjusted survival model. (Table 
I in the Data Supplement) The added predictive ability of the new 
predictor (baseline FFR) over and above a reference model (post-PCI 
FFR) was assessed by integrated discrimination improvement index 
based on logistic model.21 Kaplan–Meier curves were constructed for 
the primary end point of VOCE at 2-year follow-up. Two sided P 
values were reported throughout and P values smaller than 0.05 were 
considered as statistically significant. Analyses were performed with 
Prism GraphPad 5.0 (GraphPad Software, Inc, CA), SPSS 20.0 (IBM, 
Inc, New York), and Stata 14.0 (Stata Corp, College Station, TX).
Results
Patients and Vessels
Of the 509 patients randomized to the FFR-guided arm in the 
FAME 1 trial, 352 had post-PCI FFR measurement (69.2%). 
Of the 447 patients randomized to PCI plus medical therapy 
in the FAME 2 trial, 287 (64.2%) had post-PCI FFR measure-
ment. Together, these 639 patients constitute the study group 
of the present analysis. The baseline characteristics of the 
patient group are summarized in Table 1. Patients from the 
FAME 1 and FAME 2 trials were similar, except for the higher 
rate of hypertension and more imbalanced angina severity as 
defined by the Canadian Cardiovascular Society classification 
in the FAME 2 population.
In these 639 patients, 838 vessels were evaluated in the 
present analysis, of which 433 (51.7%) were left anterior 
descending (LAD), 217 (25.9%) were right coronary arteries, 
and 188 (22.4%) were circumflex arteries. The median value 
of baseline FFR measurements was 0.68 (0.54–0.74): 0.69 
(0.58–0.75) in the LAD, 0.66 (0.50–0.74) in the circumflex 
Table 2. Angiographic, Functional, and Procedural 
Characteristics of the Index Vessels
 
Total 
(n=838)
FAME 1 
(n=505)
FAME 2 
(n=333) P Value
Target vessel, n (%)
  LAD 433 (52) 229 (45) 204 (61)  
  LCx 188 (22) 124 (25) 64 (19)  
  RCA 217 (26) 152 (30) 65 (20) <0.001
Baseline diameter stenosis, n (%)
  <50% 23 (3) 21 (4) 2 (1)  
  50%–70% 287 (34) 174 (34) 113 (34)  
  71%–90% 397 (47) 216 (43) 181 (54)  
  >90% 127 (15) 90 (18) 37 (12) <0.001
Serial stenoses, n (%) 225 (26) 195 (38) 30 (9) <0.001
Baseline FFR, 
mean±SD
0.63±0.14 0.61±0.15 0.67±0.12 <0.001
No. of stents, mm, 
mean±SD
1.3±0.6 1.3±0.6 1.3±0.6 0.696
Total stent length, 
mm, mean±SD
23±13 23±12 27±14 <0.001
Post-PCI FFR; 
mean±SD
0.90±0.06 0.90±0.07 0.90±0.06 0.595
Comparison of population from the FAME 1 and FAME 2 trials. FAME 
indicates Fractional Flow Reserve or Angiography for Multivessel Evaluation; 
FFR, fractional flow reserve; LAD, left anterior descending; LCx, left circumflex; 
PCI, percutaneous coronary intervention; and RCA, right coronary artery.
Table 3. Predictive Value of Different Clinical and Angiographic Characteristics on the Post-
PCI FFR Value
Variable Unstandardized, β 95% CI
Standardized 
Coefficient, β 95% CI P Value
Male sex −0.017 −0.028 to −0.007 −0.113 −0.182 to −0.044 0.001
Diabetes mellitus −0.011 −0.021 to −0.001 −0.079 −0.148 to −0.009 0.026
LAD stenosis −0.043 −0.051 to −0.035 −0.340 −0.403 to −0.277 <0.001
Baseline DS 0.013 0.007 to 0.018 0.156 0.090 to 0.223 <0.001
Baseline FFR 0.036 0.006 to 0.066 0.081 0.014 to 0.148 0.019
No. of stents −0.007 −0.014 to 0.001 −0.067 −0.134 to 0.001 0.052
CI indicates confidence interval; DS, diameter stenosis; FFR, fractional flow reserve; LAD, left anterior descending; 
and PCI, percutaneous coronary intervention.
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arteries, and 0.64 (0.50–0.74) in the right coronary arteries. 
The median value of post-PCI FFR measurements was 0.90 
(0.86–0.94). The distribution is indicated in Figure 1. Detailed 
lesion and procedural characteristics are reported in Table 2. 
No relationship was found between baseline FFR and post-
PCI FFR values (Figure I in the Data Supplement). Lesions 
were more frequently located in the LAD. However, serial ste-
noses occurred more often in the FAME 1 trial in which mean 
baseline FFR was also lower. Still, the mean post-PCI FFR 
value was similar between the 2 study populations.
By computing standardized coefficient in multiple regres-
sion analysis, male sex, diabetes mellitus, and LAD loca-
tion were found as significant predictors of a lower post-PCI 
FFR value, whereas use of multiple stents in the given vessel 
showed a strong trend to predict lower post-PCI FFR value. 
Higher baseline DS and higher baseline FFR predict higher 
post-PCI FFR value (Table 3). Comparison between extended 
(post-PCI FFR+baseline FFR) and reference (post-PCI FFR 
alone) models shows that there is a small difference between 
their predictive ability (integrated discrimination improve-
ment=0.00565; z=2.53; P=0.012).
Clinical Follow-Up
Complete follow-up was obtained for 93.8% of the patients. 
The mean follow-up was 23.6±2.8 months (time to censored 
event between 0 and 24 months). Altogether, 69 events were 
detected in 58 treated vessels (6.9%). The distribution is indi-
cated in Figure 2. Baseline FFR values did not differ between 
vessels with versus without VOCE (0.66; 95% confidence 
interval [CI], 0.63–0.69 versus 0.63; 95% CI, 0.62–0.64, 
respectively; P=0.207). Post-PCI FFR was significantly lower 
in vessels with VOCE during follow-up (0.88; 95% CI, 0.87–
0.90 versus 0.90; 95% CI, 0.89–0.90, respectively; P=0.019).
When grouping the vessels in tertiles according to the 
post-PCI FFR value (<0.88 versus 0.88–0.92 versus >0.92; 
Table 4), a significant difference was found in the rate of 
VOCE with lowest incidence in the upper tertile (9.2% versus 
7.9% versus 3.8%, respectively; P=0.029).
Comparing the 2-year outcome of lower and upper tertiles 
of post-PCI FFR, a significant difference was found favoring 
the upper tertile in terms of overall VOCE (9.2% versus 3.8%, 
respectively; hazard ratio [HR], 1.46; 95% CI, 1.02–2.08; 
P=0.037) and TVR (7.0% versus 2.4%, respectively; HR, 
Figure 2. Rate of lesions with vessel-oriented composite end 
point (VOCE) in the different post–percutaneous coronary inter-
vention (PCI) fractional flow reserve strata.
Table 4. Clinical, Angiographic, Functional, and Procedural 
Characteristics
 
Lower 
(n=284)
Middle 
(n=263)
Upper 
(n=291) P Value
Male sex, n (%) 241 (85) 203 (77) 224 (77) 0.031
Age, y, mean±SD 64±10 64±10 64±10 0.876
BMI, kg/m2, mean±SD 28±4 28±5 28±4 0.898
HTN, n (%) 209 (74) 167 (64) 189 (65) 0.128
HLP, n (%) 216 (76) 193 (74) 223 (77) 0.902
DM, n (%) 82 (29) 65 (25) 55 (19) 0.059
Smoker, n (%) 59 (21) 65 (25) 72 (24) 0.520
Family history, n (%) 127 (45) 92 (35) 135 (47) 0.015
CCS, n (%)
  0 12 (4) 12 (5) 12 (4)  
  1 58 (20) 56 (21) 70 (24)  
  2 107 (38) 108 (41) 113 (39)  
  3 71 (25) 60 (23) 58 (20)  
  4 36 (13) 27 (10) 38 (13) 0.811
Vessel, n (%)
  LAD 200 (70) 156 (59) 77 (26)  
  RCA 58 (20) 62 (24) 97 (33)  
  LCx 26 (9) 45 (17) 117 (40) <0.001
First-generation DES, 
n (%)
170 (60) 143 (54) 192 (66) 0.020
Baseline FFR, mean±SD 0.62±0.13 0.65±0.13 0.62±0.15 0.016
Serial stenoses, n (%) 93 (33) 61 (23) 71 (24) 0.031
Baseline DS, n (%)
  <50% 12 (4) 8 (3) 6 (2)  
  50%–70% 112 (39) 107 (40) 68 (23)  
  70%–90% 128 (45) 112 (43) 157 (54)  
>90% 32 (11) 36 (14) 29 (20) <0.001
No. of stents, mean±SD 1.4±0.6 1.3±0.6 1.3±0.6 0.208
Total stent length, 
mean±SD
24±14 26±14 25±11 0.580
Post-PCI FFR, mean±SD 0.83±0.05 0.90±0.02 0.96±0.02  
Various characteristics of the index vessels in the lower (<0.88), the middle 
(0.88–0.92), and the upper (>0.92) tertiles according to post-PCI FFR. BMI 
indicates body mass index; CCS, Canadian Cardiovascular Society; DES, drug-
eluting stent; DM, diabetes mellitus; DS, diameter stenosis; FFR, fractional flow 
reserve; HLP, hyperlipidemia; HTN, hypertension; LAD, left anterior descending; 
LCx, left circumflex; PCI, percutaneous coronary intervention; and RCA, right 
coronary artery.
5  Piroth et al  Prognostic Value of Post-PCI FFR
1.59; 95% CI, 1.03–2.46; P=0.037). No difference was found 
in vessel-related spontaneous MI or in vessel-related mortal-
ity. Comparing the 2-year outcome of middle and upper ter-
tiles of post-PCI FFR, no significant difference was found in 
overall VOCE, TVR, spontaneous MI, or vessel-related mor-
tality (Figure 3; Table 5).
When adjusted to sex, hypertension, diabetes mellitus, 
target vessel, serial stenosis, and baseline percentage DS, a 
strong trend was preserved in terms of TVR (HR, 1.55; 95% 
CI, 0.97–2.46; P=0.066) favoring the upper tertile compared 
with the lower, as shown in Table 5.
Definition of a Potential Cutoff Value
Receiver–operator characteristic curve analysis was performed 
to identify a potential cutoff with prognostic value for VOCE 
during 2-year follow-up (Figure 4). Post-PCI FFR <0.92 has the 
highest Youden index. Accordingly, when comparing the 2-year 
outcome of vessels with post-PCI FFR <0.92 and vessels with 
post-PCI FFR ≥0.92, a significant difference was found in terms 
of overall VOCE (8.7% versus 4.2%, respectively; HR, 2.14; 
95% CI, 1.19–3.84; P=0.011). The difference remained signifi-
cant even after adjusting to sex, diabetes mellitus, target vessel, 
baseline percentage DS, and use of first-generation DES (HR, 
1.87; 95% CI, 1.01–3.46; P=0.045). Yet, sensitivity and speci-
ficity of this 0.92 post-PCI FFR cutoff value to predict vessel-
related events are low: 75.4% (95% CI, 62.2–85.9) and 43.3% 
(95% CI, 39.8–46.8), respectively. Accordingly, no post-PCI 
FFR value was found to have a HR >1.5 for VOCE at 2 years.
Discussion
Summary of Findings
The present study analyzes the relationship between the post-
PCI FFR value immediately after DES implantation and the 
vessel-related events. The main findings of the present analy-
sis can be summarized as follows:
1. Vessels with a lower residual FFR after PCI with implan-
tation of at least one DES had significantly more clinical 
events compared with vessels with higher post-PCI FFR 
values. The difference was preserved as a strong trend 
even after adjustment for various clinical, angiographic, 
and procedural characteristics. Therefore, these findings 
extend the overall prognostic value of FFR to post-PCI 
measurements.
2. Male sex, diabetes mellitus, LAD lesion location, and 
the use of multiple stents are associated with a lower 
Figure 3. Two-year vessel-related event rates in lower, middle, and high post–percutaneous coronary intervention (PCI) fractional flow 
reserve (FFR) tertiles. In the unadjusted comparison of the 2-year outcome of the tertiles, grouped according to post-PCI FFR value, a 
significant difference was found in terms of overall vessel-oriented composite end point and target vessel revascularization, favoring the 
upper tertile. No statistically significant difference was observed in vessel-related spontaneous myocardial infarction and vessel-related 
cardiovascular death. CI indicates confidence interval; and HR, hazard ratio.
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post-PCI FFR achieved after angiographically success-
ful revascularization.
3. Nevertheless, the low likelihood ratio indicates that there 
is no discrete post-PCI FFR value that could be proposed 
to rule in or to rule out vessel-oriented adverse events. 
Accordingly, post-PCI FFR cannot be advocated as a 
clinical surrogate nor as a guide for PCI optimization.
Previous Data With Post-PCI FFR
The present findings derived from the largest population 
studied to date confirm previous observational registries, 
suggesting the prognostic value of post-PCI FFR. In the bare 
metal stent era, a large registry showed a clear relationship 
between the FFR, measured immediately after PCI, and the 
MACE rate at 6-month follow-up.22 In the DES era, Doh et al23 
investigated 117 lesions in 105 patients and identified a post-
PCI FFR cutoff value of 0.89 as the best predictor of target 
vessel failure–free survival at 3 years, defined as composite 
of TVR, death, or nonfatal MI attributed to the target vessel. 
Nam et al24 investigated 99 lesions in 80 patients and found 
the cutoff value of 0.91 as strongest predictor of MACE at 
1 year. Other observational studies yielded conflicting results 
Table 5. Two-Year Clinical Outcome in the Tertiles According to Post-PCI FFR
 Lower (n=284) Middle (n=263) Upper (n=291) HR (95% CI) P Value
Unadjusted
  VOCE, n (%) 26 (9)  11 (4) 1.46 (1.02–2.08) 0.037
  Death, n (%) 6 (2)  2 (1) 1.70 (0.77–3.79) 0.191
  Spontaneous MI, n (%) 6 (2)  2 (1) 1.71 (0.77–3.78) 0.188
  TVR, n (%) 20 (7)  7 (3) 1.59 (1.03–2.46) 0.037
Adjusted for sex, hypertension, diabetes mellitus, target vessel, serial stenosis, and baseline %DS
  VOCE, n (%)    1.40 (0.93–2.08) 0.104
  Death, n (%)    1.34 (0.42–4.48) 0.602
  Spontaneous MI, n (%)    1.92 (0.94–3.94) 0.074
  TVR, n (%)    1.55 (0.97–2.46) 0.066
Unadjusted
  VOCE, n (%)  21 (8) 11 (4) 1.37 (0.61–3.09) 0.444
  Death, n (%)  5 (2) 2 (1) 1.45 (0.25–8.55) 0.685
  Spontaneous MI, n (%)  7 (3) 2 (1) 3.39 (0.71–16.39) 0.128
  TVR, n (%)  14 (5) 7 (2) 1.48 (0.53–4.13) 0.460
Adjusted for sex, diabetes mellitus, target vessel, baseline %DS, and use of first-generation DES
  VOCE, n (%)    1.01 (0.45–2.28) 0.978
  Death, n (%)    1.63 (0.18–14.89) 0.668
  Spontaneous MI, n (%)    3.06 (0.73–12.82) 0.126
  TVR, n (%)    1.17 (0.42–3.30) 0.764
Unadjusted (above) and adjusted (below) comparisons of 2-year clinical outcome of lower (<0.88) vs upper (>0.92), 
and middle (0.88–0.92) vs upper (>0.92) tertiles according to post-PCI FFR value. CI indicates confidence interval; 
DES, drug-eluting stent; %DS, percent diameter stenosis; FFR, fractional flow reserve; HR, hazard ratio; MI, myocardial 
infarction; TVR, target vessel revascularization; and VOCE, vessel-oriented composite end point.
Figure 4. Definition of a 
potential cutoff value of 
post–percutaneous coro-
nary intervention (PCI) frac-
tional flow reserve (FFR), 
predicting vessel-oriented 
composite end point at 
2-year follow-up. On the 
basis of receiver–operator 
characteristic curve analysis 
(A), a post-PCI FFR value of 
0.915 was found to have the 
highest Youden index for 
predicting VOCE at 2 years, 
with a sensitivity of 75% 
and specificity of 43% (B).
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on the ability of post-PCI FFR to predict TLR, long-term 
event-free survival, or restenosis.25–28 In contrast, the present 
analysis was based on 2 large-scale, multicentric randomized 
trials. Approximately two thirds of the total population that 
underwent FFR-guided DES placement in these trials had 
post-PCI FFR measurements. Consequently, the number of 
patients included in the present analysis is twice as large as 
most of the previously published studies from the DES era 
together.23–27 The end point—VOCE—was used to match as 
closely as possible post-PCI vessel characteristics and patients 
clinical outcome. Moreover, all end points were adjudicated 
by an independent clinical event committee blinded to all 
clinical data including post-PCI FFR values.
Evaluation of Post-PCI Results
In the vast majority of PCI cases, final results are gauged by 
angiography. A residual stenosis of >20% has often been con-
sidered a suboptimal post-PCI result.29–31 Many of the mecha-
nisms of early and late post-PCI failure have been unraveled 
by intravascular ultrasound. However, intravascular ultra-
sound-based guidance of PCI did not consistently translate 
into improved clinical outcome32,33 and was, therefore, not 
adopted in clinical practice to evaluate the result of PCI. Opti-
cal coherence tomography further improved the visualization 
of morphological details. Even though post-PCI optical coher-
ence tomography images often trigger additional maneuvers 
aiming at improving the immediate results,34,35 there is no con-
vincing indication that a systematic use of optical coherence 
tomography improves clinical outcome. An imaging modality 
focuses on the stented segment, not taking into account the 
entire length of the artery nor the myocardial mass depending 
on the stented segment. In contrast, post-PCI FFR is a marker 
of the residual epicardial resistance of the entire artery dur-
ing maximal microvascular vasodilation. Several mechanisms 
can concur to a post-PCI FFR value <1.0: the presence of a 
second lesion, residual diffuse disease, pressure sensor drift, 
and suboptimal stent deployment.36 Accordingly, the different 
mechanisms might have different weight in determining clini-
cal outcome. A pullback maneuver of the sensor under steady-
state hyperemia is able to identify which one is prevailing.37 
In case of abnormal FFR related to a pressure gradient within 
the stented segment, additional intracoronary imaging is war-
ranted to unravel the mechanism of this focal pressure drop. In 
the patients included in the FAME trials, a pressure pull back 
was not performed systematically and, when done, additional 
maneuvers to correct and improve FFR were not advocated. 
However, daily experience shows that after an angiographi-
cally successful PCI, the pressure gradient is often diffusely 
distributed over the length of the artery caused by diffuse ath-
erosclerosis, which may or may not be visible by angiography. 
FFR values measured in the present study were obtained when 
the PCI was considered successful and should, therefore, be 
considered merely documentary.
Perspectives
Our findings raise the question whether optimization of post-
PCI FFR with a more extensive intervention could improve 
clinical outcome. An answer to this question could only be 
derived from an appropriately sized trial. On the basis of the 
present findings, such a randomized trial comparing post-
PCI FFR-based optimization with routine practice would 
require ≈4200 patients to detect a 30% relative risk reduction 
of VOCE at 2 years (from 7.9% in the control group receiv-
ing routine care to 3.6% in the experimental group with 80% 
power at a 2-sided α of 0.05). In the light of our results, such 
a trial currently seems hardly justifiable.
Limitations
It is important to stress that the post-PCI values were merely 
documentary because, after angiographically successful PCI, 
according to protocol, no additional maneuver was under-
taken to achieve a higher FFR value. Second, patients and 
their treating physicians could be aware of the post-PCI FFR 
value. However, all patients had angiographically successful 
PCI, and the vast majority had a nonsignificant FFR on com-
pletion of the intervention (Figure 1). Third, albeit measure-
ment of post-PCI FFR was recommended in the trials, it was 
performed only in two thirds of all cases, suggesting some 
selection bias. It can indeed be speculated that post-PCI FFR 
measurements were preferentially performed in cases with 
a good angiographic result. Yet, this potential selection bias 
could actually only strengthen our findings. Fourth, we did 
not specifically investigate the effect of medical therapy and 
compliance of patients with the medical regimen; however, 
both trials mandated optimal medical therapy, and the FAME 
2 trial reported on the medical therapy of different arms of 
the trial.6,7 Finally, because post-PCI pullback recording dur-
ing constant hyperemia was not mandated, we are unable to 
tell whether a suboptimal post-PCI FFR value is a result of 
residual diffuse coronary atherosclerosis, imperfect stenting, 
or pressure drift.
Clinical Implications
The higher the post-PCI FFR value, obtained immediately 
after DES implantation, the lower the 2-year rate of clini-
cal events related to the stented vessel. However, the present 
data cannot propose a discrete post-PCI FFR cutoff value that 
might be used as a surrogate clinical end point or as a target 
value to optimize PCI results.
Sources of Funding
Present subanalysis was not supported by any additional industrial 
funding or research grant.
Disclosures
Dr Toth has consultancy agreement with St. Jude Medical/Abbott. Dr 
Barbato declares that the Cardiovascular Center Aalst receives on his 
behalf grant support from Abbott, Boston Scientific, Biotronik, and St 
Jude Medical and consulting fees from St. Jude Medical and Boston 
Scientific outside of the submitted work. Dr Curzen declares that he 
has received grant support from Boston Scientific, Haemonetics, and 
HeartFlow; consulting/speaker fees from Boston Scientific, Abbott, 
Haemonetics, and HeartFlow; travel sponsorship from Abbott, Lilly/
DS, St Jude Medical, and Biosensors. Dr Pijls is consultant for St. 
Jude Medical, Inc, Opsens, Inc, and Boston Scientific, Inc, outside 
the submitted work and is a shareholder for Philips, Inc, ASML, Inc, 
Genaral Electrics, Inc, and Heartflow, Inc. Dr Fearon reports research 
support from Medtronic and St. Jude Medical, Inc, outside the sub-
mitted work and consultant fee from Medtronic and HeartFlow. Dr 
Jüni has received research grants to the institution from Astra Zeneca, 
8  Piroth et al  Prognostic Value of Post-PCI FFR
Biotronik, Biosensors International, Eli Lilly, and The Medicines 
Company and serves as unpaid member of the steering group of trials 
funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical, and 
The Medicines Company. Dr Bruyne declares that the Cardiovascular 
Center Aalst receives on his behalf grant support from Abbott, Boston 
Scientific, Biotronik, and St Jude Medical and consulting fees from 
St. Jude Medical, Opsens, and Boston Scientific outside of the sub-
mitted and is shareholder for Siemens, GE, Bayer, Philips, Heartflow, 
Edwards Life-Sciences, Sanofi, and Omega Pharma. The other au-
thors report no conflicts.
References
 1. Pijls NHJ, van Son JAM, Kirkeeide RL, De Bruyne B, Gould KL. 
Experimental basis of determining maximum coronary, myocardial, and 
collateral blood flow by pressure measurement for assessing functional 
stenosis severity before and after percutaneous transluminal coronary an-
gioplasty. Circulation. 1993;86:1354–1367.
 2. De Bruyne B, Baudhuin T, Melin JA, Pijls NH, Sys SU, Bol A, Paulus WJ, 
Heyndrickx GR, Wijns W. Coronary flow reserve calculated from pressure 
measurements in humans. Validation with positron emission tomography. 
Circulation. 1994;89:1013–1022.
 3. Toth G, Hamilos M, Pyxaras S, Mangiacapra F, Nelis O, De Vroey F, Di 
Serafino L, Muller O, Van Mieghem C, Wyffels E, Heyndrickx GR, Bartunek 
J, Vanderheyden M, Barbato E, Wijns W, De Bruyne B. Evolving concepts of 
angiogram: fractional flow reserve discordances in 4000 coronary stenoses. 
Eur Heart J. 2014;35:2831–2838. doi: 10.1093/eurheartj/ehu094.
 4. Bech GJ, De Bruyne B, Pijls NHJ, de Muinck ED, Hoorntje JC, Escaned 
J, Stella PR, Boersma E, Bartunek J, Koolen JJ, Wijns W. Fractional flow 
reserve to determine the appropriateness of angioplasty in moderate coro-
nary stenosis: a randomized trial. Circulation. 2001;103:2928–2934.
 5. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van’ t Veer 
M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, 
MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow 
reserve versus angiography for guiding percutaneous coronary interven-
tion. N Engl J Med. 2009;360:213–224. doi: 10.1056/NEJMoa0807611.
 6. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic 
N, Möbius-Winkler S, Mobius-Winckler S, Rioufol G, Witt N, Kala P, 
MacCarthy P, Engström T, Oldroyd KG, Mavromatis K, Manoharan G, 
Verlee P, Frobert O, Curzen N, Johnson JB, Jüni P, Fearon WF; FAME 
2 Trial Investigators. Fractional flow reserve-guided PCI versus medical 
therapy in stable coronary disease. N Engl J Med. 2012;367:991–1001. 
doi: 10.1056/NEJMoa1205361.
 7. De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, Piroth Z, Jagic 
N, Mobius-Winckler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström 
T, Oldroyd K, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen 
N, Johnson JB, Limacher A, Nüesch E, Jüni P; FAME 2 Trial Investigators. 
Fractional flow reserve-guided PCI for stable coronary artery disease. N 
Engl J Med. 2014;371:1208–1217. doi: 10.1056/NEJMoa1408758.
 8. Zimmermann FM, Ferrara A, Johnson NP, van Nunen LX, Escaned J, 
Albertsson P, Erbel R, Legrand V, Gwon HC, Remkes WS, Stella PR, van 
Schaardenburgh P, Bech GJ, De Bruyne B, Pijls NH. Deferral vs. perfor-
mance of percutaneous coronary intervention of functionally non-signifi-
cant coronary stenosis: 15-year follow-up of the DEFER trial. Eur Heart 
J. 2015;36:3182–3188. doi: 10.1093/eurheartj/ehv452.
 9. van Nunen LX, Zimmermann FM, Tonino PA, Barbato E, Baumbach A, 
Engstrøm T, Klauss V, MacCarthy PA, Manoharan G, Oldroyd KG, Ver 
Lee PN, Van’t Veer M, Fearon WF, De Bruyne B, Pijls NH; FAME Study 
Investigators. Fractional flow reserve versus angiography for guidance of 
PCI in patients with multivessel coronary artery disease (FAME): 5-year 
follow-up of a randomised controlled trial. Lancet. 2015;386:1853–1860. 
doi: 10.1016/S0140-6736(15)00057-4.
 10. Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee 
PN, Maccarthy PA, Van’t Veer M, Pijls NH. Angiographic versus function-
al severity of coronary artery stenoses in the FAME study fractional flow 
reserve versus angiography in multivessel evaluation. J Am Coll Cardiol. 
2010;55:2816–2821. doi: 10.1016/j.jacc.2009.11.096.
 11. De Bruyne B, Pijls NH, Bartunek J, Kulecki K, Bech JW, De Winter 
H, Van Crombrugge P, Heyndrickx GR, Wijns W. Fractional flow 
reserve in patients with prior myocardial infarction. Circulation. 
2001;104:157–162.
 12. Hamilos M, Muller O, Cuisset T, Ntalianis A, Chlouverakis G, Sarno G, 
Nelis O, Bartunek J, Vanderheyden M, Wyffels E, Barbato E, Heyndrickx 
GR, Wijns W, De Bruyne B. Long-term clinical outcome after fractional 
flow reserve-guided treatment in patients with angiographically equivocal 
left main coronary artery stenosis. Circulation. 2009;120:1505–1512. doi: 
10.1161/CIRCULATIONAHA.109.850073.
 13. Muller O, Mangiacapra F, Ntalianis A, Verhamme KM, Trana C, Hamilos 
M, Bartunek J, Vanderheyden M, Wyffels E, Heyndrickx GR, van Rooij 
FJ, Witteman JC, Hofman A, Wijns W, Barbato E, De Bruyne B. Long-
term follow-up after fractional flow reserve-guided treatment strategy in 
patients with an isolated proximal left anterior descending coronary ar-
tery stenosis. JACC Cardiovasc Interv. 2011;4:1175–1182. doi: 10.1016/j.
jcin.2011.09.007.
 14. Puymirat E, Peace A, Mangiacapra F, Conte M, Ntarladimas Y, Bartunek 
J, Vanderheyden M, Wijns W, De Bruyne B, Barbato E. Long-term clinical 
outcome after fractional flow reserve-guided percutaneous coronary revas-
cularization in patients with small-vessel disease. Circ Cardiovasc Interv. 
2012;5:62–68. doi: 10.1161/CIRCINTERVENTIONS.111.966937.
 15. Di Serafino L, De Bruyne B, Mangiacapra F, Bartunek J, Agostoni P, 
Vanderheyden M, Scognamiglio G, Heyndrickx GR, Wijns W, Barbato 
E. Long-term clinical outcome after fractional flow reserve- versus angio-
guided percutaneous coronary intervention in patients with intermediate 
stenosis of coronary artery bypass grafts. Am Heart J. 2013;166:110–118. 
doi: 10.1016/j.ahj.2013.04.007.
 16. Toth G, De Bruyne B, Casselman F, De Vroey F, Pyxaras S, Di Serafino L, 
Van Praet F, Van Mieghem C, Stockman B, Wijns W, Degrieck I, Barbato 
E. Fractional flow reserve-guided versus angiography-guided coronary ar-
tery bypass graft surgery. Circulation. 2013;128:1405–1411. doi: 10.1161/
CIRCULATIONAHA.113.002740.
 17. Pijls NH, Fearon WF, Tonino PA, Siebert U, Ikeno F, Bornschein B, van’t 
Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, 
MacCarthy PA, De Bruyne B; FAME Study Investigators. Fractional 
flow reserve versus angiography for guiding percutaneous coronary in-
tervention in patients with multivessel coronary artery disease: 2-year 
follow-up of the FAME (Fractional Flow Reserve Versus Angiography for 
Multivessel Evaluation) study. J Am Coll Cardiol. 2010;56:177–184. doi: 
10.1016/j.jacc.2010.04.012.
 18. Johnson NP, Tóth GG, Lai D, Zhu H, Açar G, Agostoni P, Appelman 
Y, Arslan F, Barbato E, Chen SL, Di Serafino L, Domínguez-Franco 
AJ, Dupouy P, Esen AM, Esen OB, Hamilos M, Iwasaki K, Jensen LO, 
Jiménez-Navarro MF, Katritsis DG, Kocaman SA, Koo BK, López-Palop 
R, Lorin JD, Miller LH, Muller O, Nam CW, Oud N, Puymirat E, Rieber 
J, Rioufol G, Rodés-Cabau J, Sedlis SP, Takeishi Y, Tonino PA, Van Belle 
E, Verna E, Werner GS, Fearon WF, Pijls NH, De Bruyne B, Gould KL. 
Prognostic value of fractional flow reserve: linking physiologic severity to 
clinical outcomes. J Am Coll Cardiol. 2014;64:1641–1654. doi: 10.1016/j.
jacc.2014.07.973.
 19. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos 
G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, 
Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa 
Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, 
Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revasculariza-
tion. Eur Heart J. 2014;35:2541–2619.
 20. Barbato E, Toth GG, Johnson NP, Pijls NH, Fearon WF, Tonino PA, 
Curzen N, Piroth Z, Rioufol G, Jüni P, De Bruyne B. A prospec-
tive natural history study of coronary atherosclerosis using fractional 
flow reserve. J Am Coll Cardiol. 2016;68:2247–2255. doi: 10.1016/j.
jacc.2016.08.055.
 21. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating 
the added predictive ability of a new marker: from area under the ROC 
curve to reclassification and beyond. Stat Med. 2008;27:157–72; discus-
sion 207. doi: 10.1002/sim.2929.
 22. Pijls NH, Klauss V, Siebert U, Powers E, Takazawa K, Fearon WF, 
Escaned J, Tsurumi Y, Akasaka T, Samady H, De Bruyne B; Fractional 
Flow Reserve (FFR) Post-Stent Registry Investigators. Coronary pressure 
measurement after stenting predicts adverse events at follow-up: a multi-
center registry. Circulation. 2002;105:2950–2954.
 23. Doh JH, Nam CW, Koo BK, Lee SY, Choi H, Namgung J, Kwon SU, 
Kwak JJ, Kim HY, Choi WH, Lee WR. Clinical relevance of poststent 
fractional flow reserve after drug-eluting stent implantation. J Invasive 
Cardiol. 2015;27:346–351.
 24. Nam CW, Hur SH, Cho YK, Park HS, Yoon HJ, Kim H, Chung IS, Kim 
YN, Kim KB, Doh JH, Koo BK, Tahk SJ, Fearon WF. Relation of fraction-
al flow reserve after drug-eluting stent implantation to one-year outcomes. 
Am J Cardiol. 2011;107:1763–1767. doi: 10.1016/j.amjcard.2011.02.329.
 25. Matsuo A, Fujita H, Tanigaki T, Shimonaga T, Ueoka A, Tsubakimoto Y, 
Sakatani T, Kimura S, Inoue K, Kitamura M. Clinical implications of cor-
onary pressure measurement after stent implantation. Cardiovasc Interv 
Ther. 2013;28:170–177. doi: 10.1007/s12928-012-0147-7.
9  Piroth et al  Prognostic Value of Post-PCI FFR
 26. Leesar MA, Satran A, Yalamanchili V, Helmy T, Abdul-Waheed M, 
Wongpraparut N. The impact of fractional flow reserve measurement on 
clinical outcomes after transradial coronary stenting. EuroIntervention. 
2011;7:917–923. doi: 10.4244/EIJV7I8A145.
 27. Ishii H, Kataoka T, Kobayashi Y, Tsumori T, Takeshita H, Matsumoto R, 
Shirai N, Nishioka H, Hasegawa T, Nakata S, Shimada Y, Ehara S, Muro 
T, Yoshiyama M. Utility of myocardial fractional flow reserve for predic-
tion of restenosis following sirolimus-eluting stent implantation. Heart 
Vessels. 2011;26:572–581. doi: 10.1007/s00380-010-0105-1.
 28. Agarwal SK, Kasula S, Hacioglu Y, Ahmed Z, Uretsky BF, Hakeem A. 
Utilizing post-intervention fractional flow reserve to optimize acute re-
sults and the relationship to long-term outcomes. JACC Cardiovasc Interv. 
2016;9:1022–1031. doi: 10.1016/j.jcin.2016.01.046.
 29. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, 
Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, 
Kuntz RE. A clinical trial comparing three antithrombotic-drug regi-
mens after coronary-artery stenting. Stent Anticoagulation Restenosis 
Study Investigators. N Engl J Med. 1998;339:1665–1671. doi: 10.1056/
NEJM199812033392303.
 30. Di Mario C, Moses JW, Anderson TJ, Bonan R, Muramatsu T, Jain AC, 
Suarez de Lezo J, Cho SY, Kern M, Meredith IT, Cohen D, Moussa I, 
Colombo A. Randomized comparison of elective stent implantation and 
coronary balloon angioplasty guided by online quantitative angiography 
and intracoronary Doppler. DESTINI Study Group (Doppler Endpoint 
STenting INternational Investigation). Circulation. 2000;102:2938–2944.
 31. Serruys PW, de Bruyne B, Carlier S, Sousa JE, Piek J, Muramatsu T, Vrints 
C, Probst P, Seabra-Gomes R, Simpson I, Voudris V, Gurné O, Pijls N, 
Belardi J, van Es GA, Boersma E, Morel MA, van Hout B. Randomized 
comparison of primary stenting and provisional balloon angioplasty guided 
by flow velocity measurement. Doppler Endpoints Balloon Angioplasty 
Trial Europe (DEBATE) II Study Group. Circulation. 2000;102:2930–2937.
 32. Zhang Y, Farooq V, Garcia-Garcia HM, Bourantas CV, Tian N, Dong S, Li 
M, Yang S, Serruys PW, Chen SL. Comparison of intravascular ultrasound 
versus angiography-guided drug-eluting stent implantation: a meta-analy-
sis of one randomised trial and ten observational studies involving 19,619 
patients. EuroIntervention. 2012;8:855–865. doi: 10.4244/EIJV8I7A129.
 33. Parise H, Maehara A, Stone GW, Leon MB, Mintz GS. Meta-analysis 
of randomized studies comparing intravascular ultrasound versus an-
giographic guidance of percutaneous coronary intervention in pre-drug-
eluting stent era. Am J Cardiol. 2011;107:374–382. doi: 10.1016/j.
amjcard.2010.09.030.
 34. Wijns W, Shite J, Jones MR, Lee SW, Price MJ, Fabbiocchi F, Barbato 
E, Akasaka T, Bezerra H, Holmes D. Optical coherence tomography im-
aging during percutaneous coronary intervention impacts physician deci-
sion-making: ILUMIEN I study. Eur Heart J. 2015;36:3346–3355. doi: 
10.1093/eurheartj/ehv367.
 35. Meneveau N, Souteyrand G, Motreff P, Caussin C, Amabile N, 
Ohlmann P, Morel O, Lefrançois Y, Descotes-Genon V, Silvain J, Braik 
N, Chopard R, Chatot M, Ecarnot F, Tauzin H, Van Belle E, Belle L, 
Schiele F. Optical coherence tomography to optimize results of per-
cutaneous coronary intervention in patients with non-ST-elevation 
acute coronary syndrome: results of the multicenter, randomized 
DOCTORS study (Does Optical Coherence Tomography Optimize 
Results of Stenting). Circulation. 2016;134:906–917. doi: 10.1161/
CIRCULATIONAHA.116.024393.
 36. Toth GG, Johnson NP, Jeremias A, Pellicano M, Vranckx P, Fearon WF, 
Barbato E, Kern MJ, Pijls NH, De Bruyne B. Standardization of fractional 
flow reserve measurements. J Am Coll Cardiol. 2016;68:742–753. doi: 
10.1016/j.jacc.2016.05.067.
 37. Tonino PA, Johnson NP. Why is fractional flow reserve after percuta-
neous coronary intervention not always 1.0? JACC Cardiovasc Interv. 
2016;9:1032–1035. doi: 10.1016/j.jcin.2016.04.001.
